{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:06:12Z","timestamp":1790802372302,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejca.2026.117034","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:38:44Z","timestamp":1789054724000},"page":"117034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Triplet chemotherapy with Gemcitabine, Nab-paclitaxel, and S-1 achieves high response and conversion rates in advanced pancreatic cancer: A multicenter phase II study (GeNeS1S trial)"],"prefix":"10.1016","volume":"247","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6153-6456","authenticated-orcid":false,"given":"Yoshiaki","family":"Nagatani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Chayahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7629-6803","authenticated-orcid":false,"given":"Hironaga","family":"Satake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5563-5802","authenticated-orcid":false,"given":"Hisateru","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8121-5323","authenticated-orcid":false,"given":"Takeshi","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirochika","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Tobimatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Usui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiji","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7743-7038","authenticated-orcid":false,"given":"Shiro","family":"Kimbara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Funakoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Kiyota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2026.117034_bib1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"10242","key":"10.1016\/j.ejca.2026.117034_bib2","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ejca.2026.117034_bib3","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2026.117034_bib4","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"19","key":"10.1016\/j.ejca.2026.117034_bib5","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ejca.2026.117034_bib6","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2026.117034_bib7","doi-asserted-by":"crossref","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Tempero","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"27","key":"10.1016\/j.ejca.2026.117034_bib8","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1200\/JCO.20.01364","article-title":"Metastatic pancreatic cancer: ASCO guideline update","volume":"38","author":"Sohal","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2026.117034_bib9","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2026.117034_bib10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3892\/mco.2023.2694","article-title":"Real\u2011world treatment outcomes among patients with metastatic pancreatic cancer in Japan: The Tokushukai real\u2011world data project","volume":"19","author":"Shimoyama","year":"2023","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117034_bib11","article-title":"Real-world management and outcome of patients with pancreatic adenocarcinoma. Results of the Spanish RETUD gastrointestinal registry","volume":"7","author":"Macarulla","year":"2025","journal-title":"ESMO Real World Data Digit Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2026.117034_bib12","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","article-title":"FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis","volume":"17","author":"Suker","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.117034_bib13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejca.2016.05.016","article-title":"Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer","volume":"65","author":"Hamada","year":"2016","journal-title":"Eur J Cancer"},{"issue":"13","key":"10.1016\/j.ejca.2026.117034_bib14","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1200\/JCO.2012.43.3680","article-title":"Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study","volume":"31","author":"Ueno","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10041","key":"10.1016\/j.ejca.2026.117034_bib15","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","article-title":"Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)","volume":"388","author":"Uesaka","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejca.2026.117034_bib16","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/jjco\/hyn127","article-title":"Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas","volume":"39","author":"Shirasaka","year":"2009","journal-title":"Jpn J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2026.117034_bib17","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1038\/bjc.2017.128","article-title":"Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data","volume":"116","author":"Hamada","year":"2017","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2026.117034_bib18","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1038\/bjc.2012.183","article-title":"A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study","volume":"106","author":"Nakai","year":"2012","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2026.117034_bib19","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s00432-020-03442-0","article-title":"Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study","volume":"147","author":"Zong","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.117034_bib20","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00280-013-2368-6","article-title":"Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer","volume":"73","author":"Sudo","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.ejca.2026.117034_bib21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00280-020-04174-1","article-title":"Phase 1 study of Gemcitabine\/Nab-paclitaxel\/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial)","volume":"87","author":"Sai","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10409","key":"10.1016\/j.ejca.2026.117034_bib22","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ejca.2026.117034_bib23","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2016.1137","article-title":"Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101","volume":"151","author":"Katz","year":"2016","journal-title":"JAMA Surg"},{"issue":"16","key":"10.1016\/j.ejca.2026.117034_bib24","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1200\/JCO.19.02274","article-title":"Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the dutch randomized phase III PREOPANC trial","volume":"38","author":"Versteijne","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2026.117034_bib25","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/SLA.0000000000002600","article-title":"Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment With FOLFIRINOX","volume":"269","author":"Michelakos","year":"2019","journal-title":"Ann Surg"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926008154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926008154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:32:17Z","timestamp":1790800337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926008154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":25,"alternative-id":["S0959804926008154"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117034","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Triplet chemotherapy with Gemcitabine, Nab-paclitaxel, and S-1 achieves high response and conversion rates in advanced pancreatic cancer: A multicenter phase II study (GeNeS1S trial)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117034"}}